The ability to offer hope to patients with vision loss due to neovascular age-related macular degeneration (nAMD) by administering frequent intravitreal injections of anti–vascular endothelial growth factor (VEGF) has drawn attention toward identifying the optimal frequency of injections. While the labeling of 2 approved anti-VEGF agents calls for administering an injection once a month, pro re nata1 or treat-and-extend2 regimens are commonly applied in clinical practice. However, all of this attention to optimizing the injection frequency is a moot issue if patients fail to come back at the intervals that are needed for follow-up.
Musch DC. Anti-VEGF Neovascular Age-Related Macular Degeneration Treatment Adherence Requires Attention and Action. JAMA Ophthalmol. 2018;136(11):1260–1261. doi:10.1001/jamaophthalmol.2018.3595
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.